Recent Updates
Recently added Catalysts
AVXL

ARTICLES OF MERGER f -- Converted by S, created by BCL Technologies Inc., for SEC Filing

Thursday, January 25, 2007 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ARTICLES OF MERGER f -- Converted by S, created by BCL Technologies Inc., for SEC Filing

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
10.3%
average across 4 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
ANAVEX2-73
Phase 3 · Rett Syndrome

Full Press Release Details

ARTICLES OF MERGER f -- Converted by S, created by BCL Technologies Inc., for SEC Filing
ShareAdd on Google
Tags: AVXL Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 25, 2007

Biotech snapshot

Cash runway
$132M liquidity · $2M/mo burn
~49 mo
Minimal dilution risk
Lead asset
ANAVEX2-73Phase 3
Rett Syndrome →

Catalyst track record

+57%
best trade around AVXL's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AVXL.

See every catalyst's timing & PoA →